Skip to Content
Merck
CN
  • Bacterial expression of human kynurenine 3-monooxygenase: solubility, activity, purification.

Bacterial expression of human kynurenine 3-monooxygenase: solubility, activity, purification.

Protein expression and purification (2013-12-10)
K Wilson, D J Mole, M Binnie, N Z M Homer, X Zheng, B A Yard, J P Iredale, M Auer, S P Webster
ABSTRACT

Kynurenine 3-monooxygenase (KMO) is an enzyme central to the kynurenine pathway of tryptophan metabolism. KMO has been implicated as a therapeutic target in several disease states, including Huntington's disease. Recombinant human KMO protein production is challenging due to the presence of transmembrane domains, which localise KMO to the outer mitochondrial membrane and render KMO insoluble in many in vitro expression systems. Efficient bacterial expression of human KMO would accelerate drug development of KMO inhibitors but until now this has not been achieved. Here we report the first successful bacterial (Escherichia coli) expression of active FLAG™-tagged human KMO enzyme expressed in the soluble fraction and progress towards its purification.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Flavin adenine dinucleotide disodium salt hydrate, ≥95% (HPLC), powder
Roche
cOmplete Protease Inhibitor Cocktail, Tablets provided in EASYpacks
Sigma-Aldrich
Monoclonal ANTI-FLAG® M2, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Sigma-Aldrich
L-Kynurenine, ≥98% (HPLC)
Sigma-Aldrich
Isopropyl β-D-1-thiogalactopyranoside, ≥99% (TLC)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder